Direct Injection Liquid Brachytherapy Therapeutic Radioisotope Procedures For Canince Cancer

Main Category: Veterinary
Article Date: 22 Oct 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce its plans with IsoTherapeutics Group, LLC to explore the latest ground-breaking direct injection liquid brachytherapy therapeutic radioisotope procedures* for use within its canine cancer treatment centers.

As part of its plans for state-of-the-art treatment centers for canine lymphoma and other forms of cancer, PharmaCom BioVet, Inc. is greatly encouraged by the latest research results in direct injection of liquid brachytherapy radioisotopes into tumors. Recently published collaborate studies on canines and mice by IsoTherapeutics Group, LLC and Valco Instruments Company Inc. have demonstrated that direct injection procedures with an easy to prepare, high pH formulation allow for better targeting of the radioisotope treatment with less migration into other non-cancerous cells.

Recent advances in cancer treatments such as these are fundamental to the scientific basis for PharmaCom BioVet, Inc. "Part of our commitment is to support and harness these cutting-edge methodologies for both cancer treatment and prevention," asserts Gary S. Berthold, Founder and President/CEO of PharmaCom BioVet, Inc. "The meaningful research with liquid brachytherapy direct injections provides new hope for companion animal lovers and adds to the substantive treatment options portfolio within our new cancer treatment centers," Berthold added.

Berthold also stated, "While researching treatment options for our own pets, we discovered a dynamic convergence within the veterinary and cancer research industries towards providing new treatment technologies for companion animals suffering from cancer. We also discovered a significant and growing demand for companion animal cancer care, and simultaneously found that there are almost no facilities dedicated to developing and providing these new treatment programs. Based on these factors, we decided to dedicate our lives to creating canine cancer treatment centers around the country," Berthold concluded.

About PharmaCom BioVet, Inc.

PharmaCom BioVet, Inc. seeks to further the opportunities available to people who have encountered cancer in their companion animals and to offer their animals a better quality of life and longevity. PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website http://www.PharmaComBioVet.com.

About IsoTherapeutics Group, LLC

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG develops both proprietary technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website http://www.isotherapeutics.com.

Disclosure

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

*Reference: Jim Simon, Kenneth McMillan, Keith Frank of IsoTherapeutics Group LLC, Angleton, Texas. Stan Stearns, Max Loy of Valco Instruments Co. Inc., Houston, Texas

IsoTherapeutics Group, LLC